These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8305541)

  • 1. Mechanisms of action and toxicity of immunotherapy with cytokines.
    Mier JW; Atkins MB
    Curr Opin Oncol; 1993 Nov; 5(6):1067-72. PubMed ID: 8305541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.
    Atzpodien J; Kirchner H
    Klin Wochenschr; 1990 Jan; 68(1):1-11. PubMed ID: 2407894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma.
    Su X; Zhang L; Jin L; Ye J; Guan Z; Chen R; Guo T
    Cancer Biother Radiopharm; 2010 Aug; 25(4):465-70. PubMed ID: 20701541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12.
    Floros T; Tarhini AA
    Semin Oncol; 2015 Aug; 42(4):539-48. PubMed ID: 26320059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical modulation of cytotoxic drugs by cytokines: molecular mechanisms in experimental oncology.
    Kreuser ED; Wadler S; Thiel E
    Recent Results Cancer Res; 1995; 139():371-82. PubMed ID: 7597304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
    Xiang J
    Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon treatment of renal cell carcinoma. Current status and future prospects.
    Krown SE
    Cancer; 1987 Feb; 59(3 Suppl):647-51. PubMed ID: 10822464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine combinations in immunotherapy for solid tumors: a review.
    Heaton KM; Grimm EA
    Cancer Immunol Immunother; 1993 Sep; 37(4):213-9. PubMed ID: 8348559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancer.
    Oldham RK; Thurman GB; Talmadge JE; Stevenson HC; Foon KA
    Cancer; 1984 Dec; 54(11 Suppl):2795-806. PubMed ID: 6437660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for renal cell carcinoma.
    Rosenblatt J; McDermott DF
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):793-812. PubMed ID: 21763968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of interferon-alpha in solid tumours: part 1.
    Decatris M; Santhanam S; O'Byrne K
    BioDrugs; 2002; 16(4):261-81. PubMed ID: 12196039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic response modifiers in genitourinary neoplasia.
    Droller MJ
    Cancer; 1987 Aug; 60(3 Suppl):635-44. PubMed ID: 2439187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological response modifiers in cancer.
    Reang P; Gupta M; Kohli K
    MedGenMed; 2006 Nov; 8(4):33. PubMed ID: 17415315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
    Liu M; Wang H; Liu L; Wang B; Sun G
    J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of cancer: from vision to standard clinical practice.
    Huber CH; Wölfel T
    J Cancer Res Clin Oncol; 2004 Jul; 130(7):367-74. PubMed ID: 15067541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferons and interleukins in metastatic renal cell carcinoma.
    Choudhury M; Efros M; Mittelman A
    Urology; 1993 Jan; 41(1 Suppl):67-72. PubMed ID: 7678365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.